P

Pharmathen

Develops generic drugs and delivery technologies

Planning Lead

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Municipality of Pallini, Greece
HybridHybrid workplace at the Pallini premises.
Operations & LogisticsProduction Planning & Scheduling

About the job

Requirements
  • A Bachelor's degree in Logistics, Supply Chain, Business Administration, or a related field.
  • At least 7 years of proven experience in production planning, supply planning, or a similar role, preferably within a manufacturing environment.
  • In-depth knowledge and hands-on experience with SAP.
  • Strong knowledge of Microsoft Excel and Microsoft Office.
  • Strong analytical and problem-solving skills.
  • Excellent organizational and time-management skills.
  • Strong communication and cross-functional collaboration skills.
  • Very good command of English.
Responsibilities
  • Manage raw material and packaging material availability in line with the production and packaging schedule.
  • Plan and optimize open customer orders for the next 3–4 months, considering production capacity, campaign optimization, and requested delivery dates.
  • Maintain and update relevant planning information in SAP to ensure accurate and timely production planning.
  • Monitor and report key planning and operational KPIs, including OTIF performance and explanations for orders not delivered on time and/or in full, backlog and related explanations, monthly production results, and productivity projections for the following three months.
  • Maintain and update the projection file, including open customer orders and expected packing dates based on the three-month production plan.
  • Act as process owner for the Site Master Schedule, ensuring its accuracy, consistency, and alignment with business requirements.
  • Work closely with Production and other cross-functional teams to identify and address planning constraints and ensure smooth execution of the production plan.
  • Participate in relevant projects and continuous improvement initiatives.
  • Follow the Company's Quality Policy and comply with current operational standards and legislative requirements.
  • Work in accordance with the requirements of the written Policies, Standard Operating Procedures, Technical Directives, and Protocols of the company's Quality System that are related to the duties of the position.
  • Follow the rules of hygiene and control of health status as defined in the relevant Policies and Standard Operating Procedures.
Desired Qualifications
  • Production planning, supply planning, or similar-role experience within a manufacturing environment is preferred.

About the company

Pharmathen develops generic medicines and advanced drug-delivery technologies from its Greece-based manufacturing sites, exporting to branded pharmaceutical companies and patients worldwide. Its products include long-acting injectables, sustained-release formulations, and ophthalmic drugs, built on a strategy of Life Cycle Management and new technology platforms. The company operates with full vertical integration, handling research, development, manufacturing, and export, under facilities approved by the US FDA and EU. This enables it to deliver high-quality generic solutions and optimized dosage forms at scale. Pharmathen differentiates itself through a focused emphasis on drug-delivery platforms, continuous pipeline development, and end-to-end control over development and manufacturing. Its goal is to provide high-quality, affordable medicines while expanding its capabilities in innovative generic products and advanced delivery technologies for global markets.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

N/A

Headquarters

Athens, Greece

Founded

1969

Get referred to Pharmathen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Neuraxpharm's December 2024 alliance creates Europe-wide commercialization for Pharmathen's LAI pipeline.
  • CBL Patras acquisition expands peptide capacity and adds an FDA-approved manufacturing base.
  • NTC bought Pharmathen's ophthalmology unit, proving monetizable assets despite operational turmoil.

What critics are saying

  • FDA issued a 2026 warning letter and import alert over sterile manufacturing failures.
  • Reuters reported August 2026 paliperidone shortages from Pharmathen disruptions, hitting schizophrenia patients across Europe.
  • Partners Group wrote Pharmathen equity to zero in June 2026, signaling debt-driven distress and possible restructuring.

What makes Pharmathen unique

  • Pharmathen pairs drug-delivery R&D with in-house manufacturing across Greece and Europe.
  • Its 2024 Neuraxpharm pact locked Pharmathen into psychiatry long-acting injectables globally.
  • CBL Patras added FDA-approved peptide manufacturing, strengthening complex sterile capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Training Programs

Growth & Insights and Company News

6 month growth

11%

1 year growth

12%

2 year growth

12%
PR Newswire
Dec 10th, 2025
NTC acquires Pharmathen's ophthalmology business, reaching €100M revenue with Wise Equity backing

NTC, an Italian pharmaceutical company specialising in ophthalmology, has completed the acquisition of Pharmathen's ophthalmology business unit with support from its main shareholder Wise Equity. The deal adds a consolidated portfolio of glaucoma treatments to NTC's offerings. The acquisition brings NTC's revenue to approximately €100 million, with over 80% derived from ophthalmology. The company now reaches more than 100 countries through over 250 distribution partners and gains entry into the US market through its B2B model. The acquired glaucoma portfolio includes many preservative-free formulations and complements NTC's existing therapeutic areas covering antibiotic therapy, inflammation, allergies and dry eye. Globally, around 80 million people suffer from glaucoma, a number expected to reach 112 million by 2040. Wise Equity's Wisequity VI fund, launched in May 2023 with €400 million in commitments, supported the transaction.

World Pharmaceutical Frontiers
Dec 13th, 2024
Neuraxpharm and Pharmathen partner to develop LAI psychiatry therapies

Neuraxpharm and Pharmathen have signed a co-development agreement to develop long-acting injectable (LAI) therapies for the psychiatry sector.

PR Newswire
Dec 12th, 2024
Neuraxpharm And Pharmathen Enter Into Strategic Co-Development Agreement To Develop Long-Acting Injectable Therapies

New therapies will allow patients greater choice and flexibility in the control of CNS disorders. BARCELONA, Spain, DÜSSELDORF, Germany, and ATHENS, Greece, Dec. 12, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leaders in the development and supply of long-acting injectable (LAI) therapies, announce a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen's long-acting therapeutic technologies (LATT) program. Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm

Financial Times
Jun 30th, 2024
Swiss buyout firm Partners Group lands deal for stake in €900mn biotech firm

The buyout fund bought Greece-based generics manufacturer Pharmathen in 2021 for €1.6bn including debt and last year invested alongside GHO in drug manufacturing outsourcer Sterling Pharma Solutions.

Ropes & Gray
Nov 6th, 2023
Ropes & Gray Advises Pharmathen on Acquisition of CBL Patras

Ropes & Gray has advised Pharmathen, a leading European complex drug delivery and formulation developer, on its acquisition of CBL Patras, a leading vertically integrated and US-FDA approved peptide manufacturer and supplier in Europe.